CARMA Cell Therapies, Inc. is a wholly-owned subsidiary of MaxCyte, Inc. focused on advancement of novel mRNA-based cell therapies for cancer and other diseases with serious unmet needs. CARMA is a novel and proprietary platform for the development of non-viral, mRNA-based, chimeric antigen receptor (CAR) or T-cell receptor (TCR) redirected immune cell therapies. CARMA utilizes MaxCyte’s Flow Electroporation® technology for highly efficient, non-viral, delivery of one or more mRNA(s) into un-manipulated peripheral blood mononuclear cells (PBMCs) or isolated immune cells such as T- or NK-cells. CARMA offers the potential for a safer cell therapy, as a result of transient receptor expression and a non-viral delivery approach. CARMA also offers the potential for a streamlined, scalable, and cost-effective GMP manufacturing process without the complexity of virus-based products. MaxCyte expects CARMA Cell Therapies to be self-funded by 2021.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Maryland
Company HQ Country:
United States
Year Founded:
CARMA Cell Therapies was established as a wholly-owned subsidiary of MaxCyte in 2020.
Main Therapeutic Focus:
Gene/Cell Therapy
Lead Product in Development:
MCY-M11, anti-mesothelin CAR-PBMC therapy
Development Phase of Primary Product:
Phase I
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
BIO DOUBLE HELIX SPONSORS
BIO HELIX SPONSORS
